-
Ciclopirox, Bioenergetics and ER Stress in NSCLC
2026-09-17
Lu et al. show that ciclopirox suppresses non-small cell lung cancer cell growth and motility by disrupting cellular bioenergetics, increasing reactive oxygen species, and activating ER stress-associated apoptosis. The study’s integrated metabolic, phenotypic, molecular, and xenograft design provides a mechanistic framework for evaluating ciclopirox as a repurposed NSCLC candidate while highlighting important limits in translating in vitro stress responses to therapy.
-
Annexin-V Maps Cardiomyocyte Death After Cardiac I/R
2026-09-17
The reference study introduced labeled recombinant human annexin-V as an in situ method for detecting phosphatidylserine exposure during cardiomyocyte death after myocardial ischemia and reperfusion. Its time-resolved mouse experiments showed that the assay could quantify injury progression and evaluate a cell-death-blocking intervention earlier and more directly than DNA-fragmentation assays alone.
-
METTL14–DHRS4-AS1 Axis in Ulcerative Colitis
2026-09-16
The reference study identifies METTL14 as a protective regulator in ulcerative colitis and connects its m6A activity to the lncRNA DHRS4-AS1, miR-206, and A3AR. Its combined cell and DSS-colitis experiments provide a mechanistic framework for studying epitranscriptomic control of intestinal inflammation, while also highlighting the need to distinguish writer-specific biology from broader pharmacologic methylation inhibition.
-
EZ Cap™ Reagent AG for FLCN mRNA
2026-09-15
Build a controlled FLCN mRNA rescue workflow around capped transcripts, from template preparation through mTORC1 readouts. This practical guide separates study-supported findings from optimization starting points so researchers can compare mutant, wild-type, and rescue conditions without overstating translational readiness.
-
AZD1390 at the G4 Replication–ATM Checkpoint
2026-09-15
AZD1390 is an ATM kinase inhibitor for testing how G-quadruplex replication stress becomes checkpoint failure and radiosensitivity. This article develops a causal assay framework from REV1–DHX36 biology, distinguishing direct G4 tolerance defects from ATM-dependent damage signaling in cancer research.
-
Trelagliptin, RUNX2, and Osteoblastic Differentiation
2026-09-14
A 2021 study found that trelagliptin enhanced osteoblastic differentiation and mineralization in MC3T3-E1 cells while increasing RUNX2 and phosphorylated AMPKα. The findings extend investigation of this long-acting DPP-4 inhibitor beyond glycemic regulation, but remain an in vitro mechanistic observation rather than evidence of osteoporosis treatment efficacy.
-
Y-27632 Dihydrochloride: ROCK Inhibitor Workflows
2026-09-14
Y-27632 dihydrochloride provides a practical way to separate Rho–ROCK-dependent cytoskeletal effects from broader kinase activity in cell, stem-cell, epithelial, smooth-muscle, and cancer research. This guide combines assay design, concentration screening, reference-informed controls, and troubleshooting for more reproducible ROCK inhibition.
-
MDL 28170: Selective Calpain Inhibitor Guide
2026-09-13
This scenario-driven guide explains how MDL 28170, Calpain and Cathepsin B Inhibitor, Selective (SKU A4412) can be integrated into viability, apoptosis, infection, and neuroprotection workflows. It emphasizes solvent control, assay compatibility, endpoint interpretation, and evidence-based vendor selection.
-
Epinephrine Bitartrate: Reliable Cell Assays
2026-09-12
Learn how (-)-Epinephrine (+)-bitartrate, SKU B1358, can support better-controlled viability, proliferation, and cytotoxicity workflows through documented receptor activity, solubility, storage, and concentration parameters. Scenario-based guidance helps researchers separate adrenergic biology from solvent, assay, and vendor-related variability.
-
TQB3720 Activates AR/GPX4 Ferroptosis in Prostate Cancer
2026-09-12
This study identifies a mechanistic link between androgen-receptor antagonism and ferroptotic death in prostate cancer. TQB3720 suppresses AR nuclear activity, disrupts AR–SP1 control of the GPX4 promoter, and increases oxidative lipid damage, providing a preclinical framework for targeting antioxidant dependence in prostate tumors.
-
Uridine, Trisodium Salt for RNA Precision Genomics
2026-09-11
RNA-mediated genome engineering is shifting the translational conversation from delivery alone to the quality, composition, and biosynthesis of RNA inputs. This thought-leadership article examines how Uridine, Trisodium Salt can support RNA biosynthesis and RNA metabolism studies while positioning the reagent within the emerging PRINT platform for safe-harbor transgene insertion. It also separates evidence-backed applications in vascular biology from exploratory connections to precision genomics, providing practical guidance for validation, reagent handling, and translational decision-making.
-
Ruxolitinib, DRP1, and ATC Cell Death
2026-09-11
A 2024 Cell Death and Disease study identifies a mechanistic connection between JAK1/2–STAT3 signaling, DRP1-dependent mitochondrial fission, and dual apoptotic–pyroptotic death in anaplastic thyroid carcinoma. Its in vitro and in vivo findings provide a framework for evaluating pathway inhibition, mitochondrial remodeling, caspase activation, and GSDME-associated pyroptosis in ATC research.
-
Early Life Adversity, Oxytocin, and Innate Fear
2026-09-10
A 2026 Communications Biology study links early life adversity to impaired looming-evoked defensive behavior in mice through reduced oxytocin signaling in the superior colliculus. Its combination of behavioral testing, receptor manipulation, circuit tracing, and intranasal oxytocin treatment provides a mechanistic framework for studying how adverse development alters innate threat processing.
-
GlycoRNA–RBP Domains and TAT Cell Entry
2026-09-10
The reference preprint proposes that cell-surface RNA-binding proteins and glycoRNAs organize into extracellular nanodomains that regulate entry of the cell-penetrating peptide TAT. Its perturbation-based design connects surface RNA organization with peptide internalization, while also highlighting important limits for translating these findings into cell-surface proteomics workflows.
-
Brefeldin A: ER Stress Workflow Guide
2026-09-09
Use Brefeldin A to connect ER–Golgi trafficking defects with ER stress, protein quality control, and cancer-cell phenotypes in a single experimental framework. This guide pairs BFA dose–time optimization with transport imaging, apoptosis assays, migration studies, and UBR1/UBR2-centered mechanistic controls.